Jonathan McNeill - 09 Dec 2022 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Senior Vice President of Business Development
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
09 Dec 2022
Transactions value $
-$5,131
Form type
4
Filing time
13 Dec 2022, 16:05:28 UTC
Previous filing
21 Sep 2022
Next filing
11 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Award $0 +40,000 +69% $0 98,222 09 Dec 2022 Direct F1, F2
transaction DYN Common Stock Sale -$5,130 -472 -0.48% $10.87 97,750 12 Dec 2022 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (right to buy) Award $0 +63,000 $0 63,000 09 Dec 2022 Common Stock 63,000 $10.72 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 40,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023.
F2 Includes 69,072 unvested RSUs.
F3 Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F4 Includes 67,490 unvested RSUs.
F5 This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026.

Remarks:

Senior Vice President of Business Development